NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk taps Anthropic’s Claude AI, accelerating drug discovery
Novo Nordisk and Anthropic launched a partnership to accelerate medicine discovery and development. The Wegovy manufacturer will integrate Anthropic’s Claude...
Novo Nordisk Ends Collaboration with Ascendis Pharma on Metabolic Disease Technology
Novo Nordisk terminated its collaboration with Ascendis Pharma. The partnership focused on developing long-acting therapies for metabolic diseases using...
Novo Nordisk rebrands as Novo, targeting faster growth in obesity market
Novo Nordisk has rebranded to Novo for daily operations to signal a new strategic direction. The update includes a modernized version of the heritage Apis bull...
Novo Nordisk downgraded, Morgan Stanley warns of semaglutide patent cliff
Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight. Analysts cited a subdued medium-term growth outlook and the upcoming patent cliff for...
Novo Nordisk's Wegovy wins China approval for MASH, first GLP-1 liver treatment
Novo Nordisk secured approval from China's National Medical Products Administration for Wegovy to treat metabolic dysfunction-associated steatohepatitis...
Novo Nordisk Halts Heart Drug Trials, Shares Slide on Low Success Odds
Novo Nordisk stopped two late-stage clinical trials for its experimental heart disease drug, ziltivekimab. An independent data monitoring committee recommended...
Novo Nordisk semaglutide reverses obesity in 40% of children, trial finds
Novo Nordisk released initial positive results from its STEP Young Phase 3 clinical trial. The study evaluated once-weekly semaglutide combined with lifestyle...
🔴 Novo Nordisk is trading 3.08% down today after Citi cited slowing GLP-1 prescriptions
Novo Nordisk is trading at $46.05, down -3.08%, after Citi reiterated its sell rating, citing slowing GLP-1 prescriptions. - Citi also cited a 265 Danish...
Novo Nordisk Announces Strategic Collaboration to Build Quantum Chip Facility
Novo Nordisk and the Novo Nordisk Foundation established Quantum Foundry Copenhagen in Denmark. This facility will manufacture quantum chips. The initiative...
🟢 Novo Nordisk is trading 3.04% up today after Wegovy pill launch in Germany
Novo Nordisk is trading at $46.49, up 3.04% following the September 1, 2026 launch of the Wegovy pill in Germany. - Germany is the first EU market for the...
Novo Nordisk Debuts Wegovy Pill in Germany, Marking First EU Launch
Novo Nordisk will launch the tablet version of its Wegovy weight-loss drug in Germany on September 1, 2026. This release marks the first oral semaglutide...
Novo Nordisk Begins New Obesity Drug Trial in Asia
Novo Nordisk received approval to begin a Phase 3 clinical trial in South Korea for its next-generation obesity drug candidate, ZenaGamtide (amycretin). The...
🔴 Novo Nordisk is trading 3.1% down today after Deutsche Bank downgraded shares to sell
Novo Nordisk is trading 3.09% down at $45.73 after Deutsche Bank downgraded the shares to sell and cut its price target by 9%, citing heightened concerns after...
Novo Nordisk Advances Oral Wegovy in China, Targeting World's Second-Largest Market
China’s National Medical Products Administration accepted Novo Nordisk’s marketing application for the oral version of Wegovy. This marks a critical step...
🟢 Novo Nordisk is trading 3.17% up in after-hours trading as UK Foundayo launch intensifies oral obesity-drug competition
Novo Nordisk is trading 3.17% up at $48.68 after-hours, as Eli Lilly’s Foundayo became available in the UK, intensifying oral obesity-drug competition with...
🔴 Novo Nordisk is trading 3.07% down today after Eli Lilly's UK Foundayo launch
Novo Nordisk is trading 3.07% down at $47.16 after Eli Lilly launched its competing Foundayo oral weight-loss treatment in the UK on August 24, intensifying...
🟢 Novo Nordisk is trading 3% up today after JPMorgan raised 2026 sales forecasts
Novo Nordisk is trading $48.33 (+3.01%) after JPMorgan raised its 2026 sales forecast and price target. • Wegovy forecasts increased 7% to 82 billion Danish...
Novo Nordisk rises, following JPMorgan target hikes on Wegovy sales growth
Novo Nordisk shares rose as much as 2.2% on August 25, 2026. JPMorgan increased its 2026 sales expectations and stock price target for the company. Analysts...
Farallon Capital more than triples its stake in Novo Nordisk
Farallon Capital Management significantly increased its investment in pharmaceutical company Novo Nordisk, boosting its holdings by nearly 235% to 2.62 million...
Novo Nordisk tests low-dose oral Wegovy, targeting broader obesity market access
Novo Nordisk launched a Phase 3 clinical trial for an oral version of its obesity treatment, Wegovy. The study evaluates lower doses of oral semaglutide to...